Zotarolimus

This classification denotes an immunosuppressant with the molecular formula C52H79N5O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) H4GXR80IZE, chemically known as (42s)-42-deoxy-42-(1h-tetrazol-1-yl)-rapamycin but more generally known as zotarolimus, which bears US NIH Compound Identifier 9876378. European Medicines Agency schedules zotarolimus in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32090. The term ZOTAROLIMUS is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, No. 3, 2006, List 56). ZOTAROLIMUS is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Zotarolimus bears US NLM identifiers UMLS ID C1700035 and NCI Concept Code C82294. As of Q4 2014, ZOTAROLIMUS remains US FDA's Preferred Term for this commodity. Most nations, for tariff and trade purposes, schedule zotarolimus under HS 29349990 and SITC 51579. SMILES: CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)N5C=NN=N5)C)C)O)OC)C)C)C)OC.